Anika Therapeutics ANIK Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's total liabilities & equity?
- Anika Therapeutics (ANIK) reported total liabilities & equity of $179.39M in Q1 2026.
- How has Anika Therapeutics's total liabilities & equity changed year-over-year?
- Anika Therapeutics's total liabilities & equity decreased by 5.9% year-over-year, from $190.61M to $179.39M.
- What is the long-term trend for Anika Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Anika Therapeutics's total liabilities & equity has grown at a -12.2% compound annual growth rate (CAGR), from $365.61M to $190.27M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.